| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/02/2006 | CA2243988C Pharmaceutical compositions containing buffered ortho ester polymers |
| 05/02/2006 | CA2192110C Active substance carrier for the controlled release of active substances in the gastrointestinal tract with delayed passage through the pylorus |
| 04/27/2006 | WO2006044986A1 Intracellular peptide delivery |
| 04/27/2006 | WO2006044856A2 Use of a2a adenosine receptor agonists |
| 04/27/2006 | WO2006044771A2 Methods and compositions for reducing toxicity of a pharmaceutical compound |
| 04/27/2006 | WO2006044577A1 Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| 04/27/2006 | WO2006044079A1 Medical devices and methods of preparation and use |
| 04/27/2006 | WO2006044063A2 Transepithelial delivery of peptides with incretin hormone activities |
| 04/27/2006 | WO2006043965A1 Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| 04/27/2006 | WO2006043705A1 Type ii cubic liquid crystal composition |
| 04/27/2006 | WO2006043644A1 Temperature-responsive depsipeptide polymer |
| 04/27/2006 | WO2006043083A2 Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy |
| 04/27/2006 | WO2006042928A1 Composition for preventing or treating stress, especially chronic and permanent bursts of stress |
| 04/27/2006 | WO2006042858A2 Complex comprising an antibiotic, a cyclodextrin and an interaction agent |
| 04/27/2006 | WO2006042857A2 Complex containing mequitazine, a cyclodextrin and an interaction agent |
| 04/27/2006 | WO2006042847A2 Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone |
| 04/27/2006 | WO2006042744A1 Animal feedstuff dyeing and animal drugs |
| 04/27/2006 | WO2006042724A2 Magnetic particles for therapy and diagnosis |
| 04/27/2006 | WO2006026185A8 Embolization |
| 04/27/2006 | WO2006014788A8 Methods of use of herbal compositions |
| 04/27/2006 | WO2006010084A3 A system for delivering therapeutic agents into living cells and cell nuclei |
| 04/27/2006 | WO2006007354A3 A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device |
| 04/27/2006 | WO2006005581A3 A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin |
| 04/27/2006 | WO2005123134A3 A controlled release delivery system for metformin |
| 04/27/2006 | WO2005120173A3 Anti-microbial activity of biologically stabilized silver nano particles |
| 04/27/2006 | WO2005118627A3 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use |
| 04/27/2006 | WO2005110491A3 Inducible dimerization of growth factor receptors for treating cancer |
| 04/27/2006 | WO2005105067A3 Aqueous solutions comprising prednisolone and a cyclodextrin derivative |
| 04/27/2006 | WO2005101004A3 Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) |
| 04/27/2006 | WO2005097202A3 Use of serum albumin binding peptides conjugates for the preparation of a medicament |
| 04/27/2006 | WO2005079757A3 Therapeutic agent carrier compositions |
| 04/27/2006 | WO2005065650A3 Aerosol formulations comprising a carboxylic acid surfactant |
| 04/27/2006 | WO2005065383A3 Oxidative reductive potential water solution, processes for producing same and methods of using the same |
| 04/27/2006 | WO2005063205A3 Injectable phosphatidylcholine preparations |
| 04/27/2006 | WO2005058153A3 Optical imaging contrast agents comprising a targeting vector linked to a fluorophore |
| 04/27/2006 | WO2005040349A3 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site |
| 04/27/2006 | WO2004032828A3 Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| 04/27/2006 | US20060089523 Embryo modification and implantation |
| 04/27/2006 | US20060089326 Immunostimulatory nucleic acid molecules |
| 04/27/2006 | US20060089307 Peptides that bind to the heparin binding domian of vegf and vegfr-2 |
| 04/27/2006 | US20060088933 Immunogenic label for detection of low concentrations of viral therapeutics/antibodies in blood; diagnosing/detecion/monitoring viral drug resistance; immunoassay |
| 04/27/2006 | US20060088598 Intravenous composition, process for producing the same and preparation thereof |
| 04/27/2006 | US20060088592 Oral formulation for delivery of poorly absorbed drugs |
| 04/27/2006 | US20060088580 Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion |
| 04/27/2006 | US20060088579 Transdermal drug delivery systems |
| 04/27/2006 | US20060088575 Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers |
| 04/27/2006 | US20060088574 Nutritional supplements |
| 04/27/2006 | US20060088573 Composition having action preventing or alleviating symtoms or diseases due to aging of blood vessels |
| 04/27/2006 | US20060088561 solidifying agent consists of long chain fatty alcohol; carrier is semi-solid at rest and liquefies upon application of shear forces |
| 04/27/2006 | US20060088558 Vitamin E TPGS fluid concentrate comprising a low percentage of water |
| 04/27/2006 | US20060088556 Topical formulation and use of buspirone |
| 04/27/2006 | US20060088551 Functional fragments of HIV-1 VPR protein and methods of using the same |
| 04/27/2006 | US20060088538 Specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells; diagnosis and therapy |
| 04/27/2006 | US20060088536 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles |
| 04/27/2006 | US20060088530 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes |
| 04/27/2006 | US20060088520 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| 04/27/2006 | US20060088518 Stable thrombin composition |
| 04/27/2006 | US20060088514 Formulation comprising a bacterial strain |
| 04/27/2006 | US20060088487 Block ethylenic copolymers comprising a vinyllactam block, cosmetic or pharmaceutical compositions containing them and cosmetic use of these copolymers |
| 04/27/2006 | US20060088475 Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase |
| 04/27/2006 | DE4227779B4 Zur Anwendung am Körper, in der Pharmazie oder in der Kosmetik bestimmte Dreiphasen-Lotion For use on the body, in pharmacy or in cosmetology certain three-phase lotion |
| 04/27/2006 | DE4215450B4 Topische Pharmazeutische Mittel und Verfahren zu ihrer Herstellung A topical pharmaceutical means and methods for their preparation |
| 04/27/2006 | DE19741739B4 Supramolekulares Paarungssystem, dessen Herstellung und Verwendung Supramolecular mating system, its preparation and use |
| 04/27/2006 | DE19640062B4 Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff The oral composition containing a swellable in aqueous medium matrix least one active pharmaceutical ingredient |
| 04/27/2006 | DE102004051245A1 Vitamin C-Solubilisat Vitamin C Solubilisate |
| 04/27/2006 | DE102004011663B4 Erythropoietin-Flüssigformulierung Erythropoietin liquid formulation |
| 04/27/2006 | CA2726144A1 Platelet-derived growth factor compositions and methods of use thereof |
| 04/27/2006 | CA2584560A1 Type ii cubic liquid crystal composition |
| 04/27/2006 | CA2584276A1 Anti-snoring composition |
| 04/27/2006 | CA2584184A1 Methods and compositions for reducing toxicity of a pharmaceutical compound |
| 04/27/2006 | CA2584124A1 Flavonoid composition for treating oral diseases |
| 04/27/2006 | CA2583937A1 Chimeric protein |
| 04/27/2006 | CA2583783A1 Complex containing mequitazine, a cyclodextrin and an interaction agent |
| 04/27/2006 | CA2583666A1 Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| 04/27/2006 | CA2583367A1 Cytotoxic formulation for combination therapy |
| 04/27/2006 | CA2583185A1 Use of a2a adenosine receptor agonists |
| 04/27/2006 | CA2582885A1 Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
| 04/26/2006 | EP1650226A1 Aminated complex-type sugar chain derivatives and process for the production thereof |
| 04/26/2006 | EP1650224A1 Composition and method for repairing nerve damage and enhancing functional recovery of nerve |
| 04/26/2006 | EP1649872A1 Sheet for guiding regeneration of mesenchymal tissue and production method thereof |
| 04/26/2006 | EP1649870A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 04/26/2006 | EP1649868A1 IL-12 as an adjuvant for Bordetella pertussis vaccines |
| 04/26/2006 | EP1649867A1 Stable thrombin composition |
| 04/26/2006 | EP1649864A1 Periodontal disease therapeutic and/or preventive composition |
| 04/26/2006 | EP1649861A2 Adjuvant compositions comprising a mineral salt and another immunostimulating compound |
| 04/26/2006 | EP1649851A2 Pregelatinized starch in a controlled release formulation |
| 04/26/2006 | EP1649850A1 Preparation of biodegradable microparticles containing a biologically active agent |
| 04/26/2006 | EP1649849A2 Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain. |
| 04/26/2006 | EP1649290A2 Stable compositions for measuring human natriuretic peptides |
| 04/26/2006 | EP1649286A2 Improved aminodextran compositions and conjugates and methods of making and using them |
| 04/26/2006 | EP1648995A2 Compositions for purifying and crystallizing molecules of interest |
| 04/26/2006 | EP1648988A1 Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations |
| 04/26/2006 | EP1648933A1 Long lasting insulin derivatives and methods thereof |
| 04/26/2006 | EP1648925A1 Bicyclic peptide imaging agents |
| 04/26/2006 | EP1648826A1 Zeolites for delivery of nitric oxide |
| 04/26/2006 | EP1648824A1 Amorphous silica particles having high absorbing capabilities and high structural characteristics |
| 04/26/2006 | EP1648527A2 Stabilization and ionic triggering of nitric oxide release |
| 04/26/2006 | EP1648518A2 Conjugated biological molecules and their preparation |
| 04/26/2006 | EP1648517A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 04/26/2006 | EP1648510A2 Rg1 antibodies and uses thereof |